T3N0 Rectal Cancer: Radiation for All?

Seminars in Radiation Oncology

Volumn 21, Issue 3, 2011, Pages 212-219

  Wo, Jennifer Y ^a   Mamon, Harvey J ^b   Ryan, David P ^a   Hong, Theodore S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANTIGEN DETECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; ENDOSCOPIC ECHOGRAPHY; HUMAN; INTESTINE FUNCTION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SEXUAL DYSFUNCTION; TUMOR DIFFERENTIATION; URINARY DYSFUNCTION;

CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 79957990025     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.02.007     Document Type: Review

References (44)

1. McDermott F.T., Hughes E.S., Pihl E., et al. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. Br J Surg 1985, 72:34-37.
2. Rich T., Gunderson L.L., Lew R., et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983, 52:1317-1329.
3. Minsky B.D., Mies C., Recht A., et al. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988, 61:1408-1416.
4. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992, 10:549-557. Gastrointestinal Tumor Study Group.
5. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324:709-715.
6. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450. NIH Consensus Conference.
7. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
8. Kapiteijn E., van de Velde C.J. European trials with total mesorectal excision. Semin Surg Oncol 2000, 19:350-357.
9. Heald R.J., Ryall R.D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1:1479-1482.
10. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
11. Enker W.E., Thaler H.T., Cranor M.L., et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995, 181:335-346.
12. Peeters K.C., Marijnen C.A., Nagtegaal I.D., et al. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246:693-701.
13. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27:5124-5130.
14. Gunderson L.L., Sargent D.J., Tepper J.E., et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 2004, 22:1785-1796.
15. Andre T., Afchain P., Barrier A., et al. Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res 2007, 1:90-97.
16. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
17. Park I.J., Kim H.C., Yu C.S., et al. Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol 2008, 15:519-525.
18. Picon A.I., Moore H.G., Sternberg S.S., et al. Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3N0M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis 2003, 18:487-492.
19. Willett C.G., Badizadegan K., Ancukiewicz M., et al. Prognostic factors in stage T3N0 rectal cancer: Do all patients require postoperative pelvic irradiation and chemotherapy?. Dis Colon Rectum 1999, 42:167-173.
20. Merchant N.B., Guillem J.G., Paty P.B., et al. T3N0 rectal cancer: Results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999, 3:642-647.
21. Kim J.S., Kim N.K., Min B.S., et al. Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: Is it beneficial?. Int J Colorectal Dis 2010, 25:1103-1110.
22. Cawthorn S.J., Parums D.V., Gibbs N.M., et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet 1990, 335:1055-1059.
23. Merkel S., Mansmann U., Siassi M., et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001, 16:298-304.
24. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 2009, 373:811-820.
25. Quirke P., Durdey P., Dixon M.F., et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2:996-999.
26. Nissan A., Stojadinovic A., Shia J., et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol 2006, 24:4078-4084.
27. Eriksen M.T., Wibe A., Haffner J., et al. Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum 2007, 50:156-167.
28. Quirke P., Steele R., Monson J., et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009, 373:821-828.
29. Guillem J.G., Diaz-Gonzalez J.A., Minsky B.D., et al. cT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26:368-373.
30. Lombardi R., Cuicchi D., Pinto C., et al. Clinically staged T3N0 rectal cancer: Is preoperative chemoradiotherapy the optimal treatment?. Ann Surg Oncol 2010, 17:838-845.
31. Bipat S., Glas A.S., Slors F.J., et al. Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-A meta-analysis. Radiology 2004, 232:773-783.
32. Beets-Tan R.G., Beets G.L., Vliegen R.F., et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001, 357:497-504.
33. Brown G., Radcliffe A.G., Newcombe R.G., et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003, 90:355-364.
34. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: Results of the MERCURY study. Radiology 2007, 243:132-139.
35. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
36. Shami V.M., Parmar K.S., Waxman I. Clinical impact of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in the management of rectal carcinoma. Dis Colon Rectum 2004, 47:59-65.
37. Kachnic L.A., Hong T.S., Ryan D.P. Rectal cancer at the crossroads: The dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol 2008, 26:350-351.
38. Schrag D., Weiser M.R., Goodman K.A., et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol 2010, 28(suppl):3511.
39. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
40. Ngan S., Fisher R., Goldstein D., et al. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol 2010, 28:15s. (suppl; abstr 3509).
41. Marijnen C.A., Nagtegaal I.D., Klein-Kranenbarg E., et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001, 19:1976-1984.
42. Marijnen C.A., Kapiteijn E., van de Velde C.J., et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002, 20:817-825.
43. Birgisson H., Pahlman L., Gunnarsson U., et al. Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005, 23:8697-8705.
44. Peeters K.C., van de Velde C.J., Leer J.W., et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients-A Dutch colorectal cancer group study. J Clin Oncol 2005, 23:6199-6206.